加拿大Stressgen生物技术公司报告,热休克蛋白(HSP)在癌症治疗和传染病控制方面取得良好结果。公司的研究人员认为,由侵入人体的微生物产生的HSP能刺激免疫应答,提示HSP在疾病治疗方面可能有多种用途。他们已从分枝杆菌中分离出两种HSP,并认为其可作为通用抗原,在各种情况下刺激免疫系统。 迄今Stressgen取得的最有希望的结果之一是在癌症研究方面。美国芝加哥大学的研究人员宣称,Stressgen的Oncocine疫苗能完全或明显抑制小鼠体内的肿瘤生长。该疫苗仅为纯化的HSP,后者单独注射于癌症部位。 该公司计划于1997年对该疫苗进行临床试验。他们将用(?)疫苗对各种类型的癌症进行试验,并选择最有希望的应用向食品和药物管理局提出申请。 Stressgen在癌症研究方面开展的大量工作是将HSP与某种抗原融合形成单个 Stressgen, a Canadian biotechnology company, reports that heat shock protein (HSP) has yielded good results in cancer treatment and control of infectious diseases. Researchers at the company believe that HSPs produced by microorganisms that invade the body stimulate the immune response, suggesting that HSP may have multiple uses in disease treatment. They have isolated two HSPs from mycobacteria and consider them as universal antigens to stimulate the immune system under various conditions. One of the most promising results so far with Stressgen has been in cancer research. Researchers at the University of Chicago claim that Stressgen’s Oncocine vaccine completely or significantly inhibits tumor growth in mice. The vaccine is only purified HSP, which is injected separately at the site of the cancer. The company plans to conduct a clinical trial of the vaccine in 1997. They will use the vaccine to test for various types of cancer and choose the most promising application from the Food and Drug Administration. A great deal of work Stressgen has done in cancer research is to fuse HSPs with a single antigen to form a single